Orally active lysophosphatidic acid receptor antagonist attenuates pancreatic cancer invasion and metastasis in vivo.
about
G-Protein-Coupled Lysophosphatidic Acid Receptors and Their Regulation of AKT SignalingAdvances in Lipidomics for Cancer Biomarkers DiscoveryLPA receptor signaling: pharmacology, physiology, and pathophysiology.Bioactive lipids, LPC and LPA, are novel prometastatic factors and their tissue levels increase in response to radio/chemotherapyThe autotaxin-lysophosphatidic acid-lysophosphatidic acid receptor cascade: proposal of a novel potential therapeutic target for treating glioblastoma multiformeTetracyclines increase lipid phosphate phosphatase expression on plasma membranes and turnover of plasma lysophosphatidate.Design of anticancer lysophosphatidic acid agonists and antagonists.Promising pharmacological directions in the world of lysophosphatidic Acid signaling.Molecular mechanisms of target recognition by lipid GPCRs: relevance for cancer.Gene regulatory networking reveals the molecular cue to lysophosphatidic acid-induced metabolic adaptations in ovarian cancer cellsLysophosphatidic acid stimulates activation of focal adhesion kinase and paxillin and promotes cell motility, via LPA1-3, in human pancreatic cancer.The Role of Lysophosphatidic Acid on Airway Epithelial Cell Denudation in a Murine Heterotopic Tracheal Transplant ModelSystems Chemo-Biology and Transcriptomic Meta-Analysis Reveal the Molecular Roles of Bioactive Lipids in Cardiomyocyte Differentiation.Modulation of Nav1.8 by Lysophosphatidic Acid in the Induction of Bone Cancer Pain.Autotaxin-Lysophosphatidic Acid: From Inflammation to Cancer Development.Limited fibrosis accompanies triple-negative breast cancer metastasis in multiple model systems and is not a preventive target.
P2860
Q26767279-31243530-D027-488B-8CF1-826F3E7ED796Q28079507-84EC83FA-607A-4040-986D-2D7924DBCDBFQ33825153-6DEFA7DA-CFAF-48C6-9A2D-1B7E5DCA74BEQ34518525-24995B6C-8C79-449D-AA63-8A4C39490F63Q35770218-E3917F9D-DBCC-4FE7-8ABE-D62C771AC818Q36731751-F3A483B4-4F25-4910-B256-763BD518EE92Q38223013-5E578EDF-D51F-4C55-9383-816BFECCDC07Q38320338-87999336-0C8C-436B-AC72-C09A8117D8FDQ38660494-C497A9DA-8DC8-45B3-BCDD-46E96EF092DDQ38753397-4FA2A1E1-86AA-4422-BB72-BB709FAD5709Q39092647-27EDF9CD-16F8-4909-AF67-DBAEDBD3FA3EQ40584786-207985C3-4462-4879-99AB-7A99C3BFF179Q41265082-ED7DACD8-6D79-4404-A41E-0290638CCEF4Q41654981-5985409C-AFC5-4D96-ADE5-42D98F4EF203Q50074055-8E32A617-5130-4ACB-B95C-9483ADA0D5C3Q55339193-9C66C04F-39B9-4AFD-9CA5-6016B2FBEB52
P2860
Orally active lysophosphatidic acid receptor antagonist attenuates pancreatic cancer invasion and metastasis in vivo.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Orally active lysophosphatidic ...... vasion and metastasis in vivo.
@en
Orally active lysophosphatidic ...... vasion and metastasis in vivo.
@nl
type
label
Orally active lysophosphatidic ...... vasion and metastasis in vivo.
@en
Orally active lysophosphatidic ...... vasion and metastasis in vivo.
@nl
prefLabel
Orally active lysophosphatidic ...... vasion and metastasis in vivo.
@en
Orally active lysophosphatidic ...... vasion and metastasis in vivo.
@nl
P2093
P2860
P1433
P1476
Orally active lysophosphatidic ...... vasion and metastasis in vivo.
@en
P2093
Chihiro Mogi
Dong-Soon Im
Fumikazu Okajima
Hideaki Tomura
Hideo Ohta
Izumi Takeyoshi
Keisuke Yanagida
Koichi Sato
Masayuki Tobo
Mayumi Komachi
P2860
P304
P356
10.1111/J.1349-7006.2012.02246.X
P577
2012-03-15T00:00:00Z